ストックスクリーナーアプリを入手
5.65
1.91%
-0.11
前日終値:
$5.76
開ける：
$5.75
24時間の取引高:
841.04K
Relative Volume:
0.66
時価総額：
$781.04M
収益：
$62.04M
当期純損益:
$-533.34M
株価収益率:
-1.4413
EPS:
-3.92
ネットキャッシュフロー:
$-473.07M
1週間 パフォーマンス:
+4.44%
1か月 パフォーマンス:
+8.86%
6か月 パフォーマンス:
-46.85%
1年 パフォーマンス:
-47.00%
1日の値動き範囲:
$5.63
$5.765
1週間の範囲:
$5.47
$5.98
52週間の値動き範囲:
$4.32
$14.45
Vir Biotechnology Inc Stock (VIR) Company Profile
名前
Vir Biotechnology Inc
セクター
電話
415-906-4324
住所
1800 OWENS STREET, SAN FRANCISCO, CA
VIR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
5.65 | 796.25M | 62.04M | -533.34M | -473.07M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-01-29 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2023-09-08 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-03-06 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-02-21 | アップグレード | Goldman | Neutral → Buy |
| 2023-01-27 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2022-09-14 | 開始されました | SVB Leerink | Outperform |
| 2022-09-09 | 開始されました | Morgan Stanley | Underweight |
| 2022-03-03 | アップグレード | Robert W. Baird | Underperform → Neutral |
| 2021-12-21 | ダウングレード | Robert W. Baird | Neutral → Underperform |
| 2021-10-25 | アップグレード | JP Morgan | Underweight → Neutral |
| 2021-09-22 | ダウングレード | Goldman | Buy → Neutral |
| 2021-06-04 | 再開されました | Robert W. Baird | Neutral |
| 2021-01-27 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2021-01-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-10-05 | 開始されました | BofA Securities | Buy |
| 2020-09-14 | アップグレード | Goldman | Neutral → Buy |
| 2020-09-11 | アップグレード | JP Morgan | Underweight → Neutral |
| 2020-08-20 | 開始されました | Needham | Buy |
| 2020-03-19 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2020-03-13 | ダウングレード | Goldman | Buy → Neutral |
| 2020-02-27 | ダウングレード | Robert W. Baird | Neutral → Underperform |
| 2020-02-04 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2019-11-14 | 開始されました | Robert W. Baird | Neutral |
| 2019-11-05 | 開始されました | Barclays | Overweight |
| 2019-11-05 | 開始されました | Cowen | Outperform |
| 2019-11-05 | 開始されました | Goldman | Buy |
| 2019-11-05 | 開始されました | JP Morgan | Overweight |
すべてを表示
Vir Biotechnology Inc (VIR) 最新ニュース
Vir Biotechnology (VIR) Soars 11.9%: Is Further Upside Left in the Stock? - MSN
Does Vir Biotechnology Inc. stock pay reliable dividendsFree Trading Psychology Coaching - jammulinksnews.com
First subject dosed in Phase I trial of Vir Biotechnology’s VIR-5525 - Yahoo Finance
Is Vir Biotechnology Inc. a good long term investmentFree Advanced Stock Screener Access - PrintWeekIndia
Don't Ignore The Insider Selling In Vir Biotechnology - 富途牛牛
Vir Biotechnology Begins Phase 1 Trial for VIR-5525 - TipRanks
Vir Biotechnology doses first patient in VIR-5525 trial - TipRanks
Vir Biotechnology doses first patient in EGFR-targeted cancer trial By Investing.com - Investing.com South Africa
Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors - Yahoo Finance
Vir Biotechnology Inc. Stock Analysis and ForecastExceptional return forecasts - Autocar Professional
What drives Vir Biotechnology Inc. stock priceUnstoppable investment returns - Autocar Professional
Vir Biotechnology: Hep B And Cancer Projects March On (NASDAQ:VIR) - Seeking Alpha
Have Insiders Sold Vir Biotechnology Shares Recently? - simplywall.st
What analysts say about Vir Biotechnology Inc. stockRapidly expanding wealth - jammulinksnews.com
Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2025 Financial Results on August 6, 2025 - Business Wire
(VIR) Investment Analysis and Advice - news.stocktradersdaily.com
Vir Biotechnology EVP Eisner sells $57k in stock By Investing.com - Investing.com Canada
Biotech IPO For The Week Ahead - RTTNews
Raymond James Initiates Vir Biotechnology(VIR.US) With Buy Rating, Announces Target Price $12 - 富途牛牛
Where Vir Biotechnology Stands With Analysts - Benzinga
Raymond James Initiates Vir Biotechnology at Outperform With $12 Price Target - MarketScreener
Unraveling Vir Biotechnology's 10.6% Spike: A Technical Deep Dive - AInvest
Unraveling Vir Biotechnology's 8.8% Surge: A Deep Dive - AInvest
How to Take Advantage of moves in (VIR) - news.stocktradersdaily.com
Vir Biotechnology Insiders Sell US$1.1m Of Stock, Possibly Signalling Caution - simplywall.st
Hepatitis D Pipeline Appears Robust With 8+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail
Is Vir Biotechnology (NASDAQ:VIR) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Long Term Trading Analysis for (VIR) - news.stocktradersdaily.com
Transcript : Vir Biotechnology, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 04 - MarketScreener
(VIR) Trading Advice - news.stocktradersdaily.com
Vir Biotechnology director Janet Napolitano sells $16,148 in stock - Investing.com Australia
Vir Biotechnology director Janet Napolitano sells $16,148 in stock By Investing.com - Investing.com UK
Vir Biotechnology Holds 2025 Annual Stockholder Meeting - TipRanks
Vir Biotechnology Inc (VIR) 財務データ
収益
当期純利益
現金流量
EPS
Vir Biotechnology Inc (VIR) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Eisner Mark | EVP and Chief Medical Officer |
Jul 17 '25 |
Sale |
5.47 |
3,586 |
19,629 |
104,618 |
0.97%
0.22%
大文字化:
|
ボリューム (24 時間):